Oncology Update – January 5, 2026: Faster Rybrevant, HER2 Combo Win, TNBC Filing and More

From FDA and EMA moves to Canadian access and BD activity, this roundup spans EGFR-mutated NSCLC, HER2-positive breast cancer, triple-negative breast cancer, pancreatic ductal adenocarcinoma, metastatic colorectal cancer, platinum-resistant ovarian cancer, prostate cancer, and squamous cell anal carcinoma, highlighting shifts that could reshape standards and coverage.

???? In this episode:

???? Subcutaneous Rybrevant FASPRO approved across all amivantamab indications, enabling about five-minute dosing and fewer administration-related reactions vs IV, supported by PALOMA 3 PK and MARIPOSA OS context in first-line EGFR-mutated NSCLC

???? Enhertu plus pertuzumab wins US first-line approval in HER2-positive metastatic breast cancer, showing a progression-free survival advantage over THP and a median PFS beyond three years in DESTINY-Breast09

???? EMA validates Datroway, datopotamab deruxtecan, for first-line TNBC in patients not candidates for PD-1 or PD-L1 therapy, based on significant OS and PFS benefit vs chemotherapy in TROPION-Breast02

???? EMA backs a double-blind, placebo-controlled Phase 3 of VCN-01 plus gemcitabine and nab-paclitaxel in first-line metastatic PDAC, endorsing OS as the primary endpoint with an adaptive design

???????? Canada: CDA recommends Opdivo plus Yervoy for first-line MSI-H or dMMR mCRC, with Ontario listing via the FAST program under provincial criteria

???? British Columbia to reimburse Fruzaqla, fruquintinib, for previously treated mCRC, supported by FRESCO-2 and FRESCO OS and PFS data

???? FDA grants Breakthrough Therapy Designation to JSKN003, a biparatopic HER2-directed ADC, for HER2-expressing platinum-resistant ovarian cancer after bevacizumab, based on pooled Phase 1–2 data

???? FDA converts rucaparib to regular approval for BRCA-mutated mCRPC after an androgen receptor pathway inhibitor, with TRITON3 confirming a radiographic PFS benefit while OS was not significant

???????? Japan approves Zynyz, retifanlimab, plus carboplatin and paclitaxel for first-line advanced squamous cell anal carcinoma, with a 37 percent risk reduction for progression or death and 47 percent serious adverse reactions

???? Johnson and Johnson completes a 3.05-billion-dollar Halda Therapeutics acquisition, adding the RIPTAC regulated induced proximity platform and HLD-0915 for prostate cancer


Chapters:
0:00 Introduction
0:08 FDA approves subcutaneous Rybrevant FASPRO for all amivantamab indications, enabling 5-minute dosing in EGFR-mutated NSCLC
0:50 Enhertu plus pertuzumab wins US first-line approval in HER2-positive metastatic breast cancer with PFS gain over THP
1:15 EMA validates Datroway, datopotamab deruxtecan, Type II variation for first-line TNBC not eligible for immunotherapy
1:43 EMA backs Phase 3 design for VCN-01 plus gemcitabine and nab-paclitaxel in first-line metastatic PDAC with OS primary endpoint
2:19 Canada’s CDA recommends Opdivo plus Yervoy for first-line MSI-H/dMMR mCRC, Ontario lists via FAST program
2:44 British Columbia to reimburse Fruzaqla, fruquintinib, for previously treated metastatic colorectal cancer
3:10 FDA grants Breakthrough Therapy Designation to JSKN003 for HER2-expressing platinum-resistant ovarian cancer after bevacizumab
3:38 FDA converts rucaparib to regular approval for BRCA-mutated mCRPC after ARPI based on TRITON3 rPFS benefit
4:09 Japan approves Zynyz, retifanlimab, plus carboplatin and paclitaxel for first-line advanced squamous cell anal carcinoma, 37 percent PFS risk reduction
4:33 Johnson and Johnson completes 3.05-billion-dollar Halda Therapeutics acquisition, adding RIPTAC platform and HLD-0915
4:57 How to reach us

???? Whether you follow subcutaneous delivery, ADC expansion, checkpoint combinations, or market access decisions, this episode distills the must-know updates guiding oncology care and coverage.

???? Stay Ahead in Oncology Research!
✅ Like, share, and subscribe for future updates on Oncology and specific diseases
✅ Visit www.lqventures.com for expert healthcare insights and consulting services
✅ Contact LucidQuest at [email protected] for strategic guidance on Oncology innovations and clinical research
???? Turn on notifications so you never miss an update!

#Oncology #OncologyUpdates #CancerResearch #NSCLC #BreastCancer #TNBC #PDAC #mCRC #OvarianCancer #ProstateCancer #SCAC #FDA #EMA #ClinicalTrials #DrugDevelopment #BiotechNews #PharmaInnovation #LucidQuest